Hosted on MSN1mon
Lilly reports positive results for Omvoh in Crohn's diseaseEli Lilly (NYSE:LLY) reported positive results from an open-label study of its drug Omvoh in the treatment of moderately to severely active Crohn's disease. The study, called VIVID-2, showed that ...
Hosted on MSN3mon
Lilly gets positive EU regulatory opinion for Omvoh for Crohn'sLilly (NYSE:LLY) has also applied to have Omvoh approved by the FDA for the treatment of moderately to severely active Crohn's disease. A decision expected in the first half of 2025.
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results